vs

Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and Orion Group Holdings Inc (ORN). Click either name above to swap in a different company.

Orion Group Holdings Inc is the larger business by last-quarter revenue ($216.3M vs $196.0M, roughly 1.1× Axsome Therapeutics, Inc.). Orion Group Holdings Inc runs the higher net margin — 2.2% vs -14.6%, a 16.7% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs 14.6%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 6.1%).

Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.

Orion Corporation, founded in 1917 and headquartered at Espoo, Finland, is a globally operating Finnish company which develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients for global markets. All of the company's manufacturing sites and the majority of its R&D units are in Finland.

AXSM vs ORN — Head-to-Head

Bigger by revenue
ORN
ORN
1.1× larger
ORN
$216.3M
$196.0M
AXSM
Growing faster (revenue YoY)
AXSM
AXSM
+50.4% gap
AXSM
65.0%
14.6%
ORN
Higher net margin
ORN
ORN
16.7% more per $
ORN
2.2%
-14.6%
AXSM
Faster 2-yr revenue CAGR
AXSM
AXSM
Annualised
AXSM
61.7%
6.1%
ORN

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
AXSM
AXSM
ORN
ORN
Revenue
$196.0M
$216.3M
Net Profit
$-28.6M
$4.7M
Gross Margin
12.0%
Operating Margin
-13.8%
Net Margin
-14.6%
2.2%
Revenue YoY
65.0%
14.6%
Net Profit YoY
61.9%
435.7%
EPS (diluted)
$-0.55
$0.12

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AXSM
AXSM
ORN
ORN
Q1 26
$216.3M
Q4 25
$196.0M
$233.2M
Q3 25
$171.0M
$225.1M
Q2 25
$150.0M
$205.3M
Q1 25
$121.5M
$188.7M
Q4 24
$118.8M
$216.9M
Q3 24
$104.8M
$226.7M
Q2 24
$87.2M
$192.2M
Net Profit
AXSM
AXSM
ORN
ORN
Q1 26
$4.7M
Q4 25
$-28.6M
$-240.0K
Q3 25
$-47.2M
$3.3M
Q2 25
$-48.0M
$841.0K
Q1 25
$-59.4M
$-1.4M
Q4 24
$-74.9M
$6.8M
Q3 24
$-64.6M
$4.3M
Q2 24
$-79.3M
$-6.6M
Gross Margin
AXSM
AXSM
ORN
ORN
Q1 26
12.0%
Q4 25
11.6%
Q3 25
13.2%
Q2 25
12.6%
Q1 25
12.2%
Q4 24
14.0%
Q3 24
11.9%
Q2 24
9.5%
Operating Margin
AXSM
AXSM
ORN
ORN
Q1 26
Q4 25
-13.8%
2.2%
Q3 25
-27.0%
2.4%
Q2 25
-24.5%
1.7%
Q1 25
-46.9%
0.4%
Q4 24
-61.1%
4.4%
Q3 24
-59.8%
3.4%
Q2 24
-89.5%
-1.4%
Net Margin
AXSM
AXSM
ORN
ORN
Q1 26
2.2%
Q4 25
-14.6%
-0.1%
Q3 25
-27.6%
1.5%
Q2 25
-32.0%
0.4%
Q1 25
-48.9%
-0.7%
Q4 24
-63.1%
3.1%
Q3 24
-61.7%
1.9%
Q2 24
-91.0%
-3.4%
EPS (diluted)
AXSM
AXSM
ORN
ORN
Q1 26
$0.12
Q4 25
$-0.55
$-0.00
Q3 25
$-0.94
$0.08
Q2 25
$-0.97
$0.02
Q1 25
$-1.22
$-0.04
Q4 24
$-1.54
$0.22
Q3 24
$-1.34
$0.12
Q2 24
$-1.67
$-0.20

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AXSM
AXSM
ORN
ORN
Cash + ST InvestmentsLiquidity on hand
$322.9M
$6.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$88.3M
$166.7M
Total Assets
$689.8M
$478.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AXSM
AXSM
ORN
ORN
Q1 26
$6.3M
Q4 25
$322.9M
$1.6M
Q3 25
$325.3M
$4.9M
Q2 25
$303.0M
$1.7M
Q1 25
$300.9M
$13.0M
Q4 24
$315.4M
$28.3M
Q3 24
$327.3M
$28.3M
Q2 24
$315.7M
$4.8M
Total Debt
AXSM
AXSM
ORN
ORN
Q1 26
Q4 25
Q3 25
Q2 25
$33.4M
Q1 25
$23.3M
Q4 24
$23.2M
Q3 24
$28.0M
Q2 24
$60.3M
Stockholders' Equity
AXSM
AXSM
ORN
ORN
Q1 26
$166.7M
Q4 25
$88.3M
$159.0M
Q3 25
$73.7M
$157.9M
Q2 25
$73.1M
$153.2M
Q1 25
$53.2M
$150.8M
Q4 24
$57.0M
$150.7M
Q3 24
$92.9M
$142.4M
Q2 24
$102.9M
$111.1M
Total Assets
AXSM
AXSM
ORN
ORN
Q1 26
$478.7M
Q4 25
$689.8M
$414.7M
Q3 25
$669.3M
$422.4M
Q2 25
$639.8M
$432.7M
Q1 25
$596.7M
$416.3M
Q4 24
$568.5M
$417.3M
Q3 24
$561.5M
$430.3M
Q2 24
$548.2M
$414.0M
Debt / Equity
AXSM
AXSM
ORN
ORN
Q1 26
Q4 25
Q3 25
Q2 25
0.22×
Q1 25
0.15×
Q4 24
0.15×
Q3 24
0.20×
Q2 24
0.54×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AXSM
AXSM
ORN
ORN
Operating Cash FlowLast quarter
$-18.7M
Free Cash FlowOCF − Capex
$-18.7M
FCF MarginFCF / Revenue
-9.6%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-93.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AXSM
AXSM
ORN
ORN
Q1 26
Q4 25
$-18.7M
$13.8M
Q3 25
$1.0M
$23.3M
Q2 25
$-32.4M
$-5.6M
Q1 25
$-43.4M
$-3.4M
Q4 24
$-26.2M
$13.4M
Q3 24
$-18.6M
$37.5M
Q2 24
$-30.1M
$-15.3M
Free Cash Flow
AXSM
AXSM
ORN
ORN
Q1 26
Q4 25
$-18.7M
$454.0K
Q3 25
$988.0K
$13.9M
Q2 25
$-32.4M
$-12.7M
Q1 25
$-43.7M
$-12.5M
Q4 24
$-26.2M
$9.9M
Q3 24
$-18.7M
$33.3M
Q2 24
$-30.2M
$-20.0M
FCF Margin
AXSM
AXSM
ORN
ORN
Q1 26
Q4 25
-9.6%
0.2%
Q3 25
0.6%
6.2%
Q2 25
-21.6%
-6.2%
Q1 25
-36.0%
-6.6%
Q4 24
-22.1%
4.6%
Q3 24
-17.9%
14.7%
Q2 24
-34.6%
-10.4%
Capex Intensity
AXSM
AXSM
ORN
ORN
Q1 26
Q4 25
0.0%
5.7%
Q3 25
0.0%
4.2%
Q2 25
0.0%
3.5%
Q1 25
0.3%
4.8%
Q4 24
0.0%
1.6%
Q3 24
0.1%
1.8%
Q2 24
0.1%
2.4%
Cash Conversion
AXSM
AXSM
ORN
ORN
Q1 26
Q4 25
Q3 25
7.05×
Q2 25
-6.61×
Q1 25
Q4 24
1.98×
Q3 24
8.79×
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons